JP2007533760A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007533760A5 JP2007533760A5 JP2007509624A JP2007509624A JP2007533760A5 JP 2007533760 A5 JP2007533760 A5 JP 2007533760A5 JP 2007509624 A JP2007509624 A JP 2007509624A JP 2007509624 A JP2007509624 A JP 2007509624A JP 2007533760 A5 JP2007533760 A5 JP 2007533760A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- carbon atoms
- composition according
- alkyl
- pde4 modulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 3-ethoxy-4-methoxy-phenyl Chemical group 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 125000004432 carbon atom Chemical group C* 0.000 claims 15
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 12
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 208000002815 pulmonary hypertension Diseases 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 2
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims 1
- LXFIMHZDTHLHOA-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-(1h-pyrrol-2-yl)isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(C=4NC=CC=4)C=CC=C3C2=O)=O)=C1 LXFIMHZDTHLHOA-UHFFFAOYSA-N 0.000 claims 1
- KYBGGKMHMYDTDS-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-(5-methyl-1,3,4-oxadiazol-2-yl)isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(C=4OC(C)=NN=4)C=CC=C3C2=O)=O)=C1 KYBGGKMHMYDTDS-UHFFFAOYSA-N 0.000 claims 1
- DHKAFTYWTCIWJX-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical group C1=C(OC)C(OC)=CC=C1C(CC(N)=O)N1C(=O)C2=CC=CC=C2C1 DHKAFTYWTCIWJX-UHFFFAOYSA-N 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims 1
- 229940097420 Diuretic Drugs 0.000 claims 1
- 229940124143 Endopeptidase inhibitor Drugs 0.000 claims 1
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 claims 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 229960000528 amlodipine Drugs 0.000 claims 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 230000004872 arterial blood pressure Effects 0.000 claims 1
- 229960003065 bosentan Drugs 0.000 claims 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229940097217 cardiac glycoside Drugs 0.000 claims 1
- 239000002368 cardiac glycoside Substances 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical group OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 1
- 229960005156 digoxin Drugs 0.000 claims 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
- 229960004166 diltiazem Drugs 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 229960001123 epoprostenol Drugs 0.000 claims 1
- 229960002240 iloprost Drugs 0.000 claims 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
- 229960001597 nifedipine Drugs 0.000 claims 1
- 229960003753 nitric oxide Drugs 0.000 claims 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 claims 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 1
- 150000003815 prostacyclins Chemical class 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims 1
- 229960003310 sildenafil Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- 229950005143 sitosterol Drugs 0.000 claims 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229930002534 steroid glycoside Natural products 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960000835 tadalafil Drugs 0.000 claims 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims 1
- 229960005032 treprostinil Drugs 0.000 claims 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 229960005080 warfarin Drugs 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56517404P | 2004-04-23 | 2004-04-23 | |
| PCT/US2005/013597 WO2005102317A1 (en) | 2004-04-23 | 2005-04-21 | Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007533760A JP2007533760A (ja) | 2007-11-22 |
| JP2007533760A5 true JP2007533760A5 (https=) | 2008-05-15 |
Family
ID=35196722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007509624A Abandoned JP2007533760A (ja) | 2004-04-23 | 2005-04-21 | 肺高血圧症を治療し管理するための、ｐｄｅ４モジュレーターの使用方法及びｐｄｅ４モジュレーターを含む組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050239867A1 (https=) |
| EP (1) | EP1755589A4 (https=) |
| JP (1) | JP2007533760A (https=) |
| KR (1) | KR20070007945A (https=) |
| CN (1) | CN1972684A (https=) |
| AU (1) | AU2005234783A1 (https=) |
| BR (1) | BRPI0510166A (https=) |
| CA (1) | CA2563377A1 (https=) |
| IL (1) | IL178788A0 (https=) |
| MX (1) | MXPA06012279A (https=) |
| WO (1) | WO2005102317A1 (https=) |
| ZA (1) | ZA200609228B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| CA2590903A1 (en) * | 2004-12-13 | 2006-06-22 | Celgene Corporation | Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation |
| NZ561746A (en) | 2005-04-19 | 2011-09-30 | Nycomed Gmbh | Roflumilast for the treatment of pulmonary hypertension |
| TW200804347A (en) | 2006-01-10 | 2008-01-16 | Janssen Pharmaceutica Nv | Urotensin II receptor antagonists |
| FR2902009B1 (fr) * | 2006-06-13 | 2012-12-07 | Bioprojet Soc Civ | Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire |
| AU2013203094B2 (en) * | 2006-07-05 | 2016-02-25 | Astrazeneca Ab | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases |
| EP2359826B1 (en) * | 2006-07-05 | 2013-10-30 | Takeda GmbH | Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases |
| EP2049120A4 (en) | 2006-07-31 | 2011-09-07 | Janssen Pharmaceutica Nv | UROTENSIN II RECEPTOR ANTAGONISTS |
| WO2008019106A1 (en) * | 2006-08-04 | 2008-02-14 | Artesian Therapeutics, Inc. | Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor |
| US20080312241A1 (en) * | 2007-01-03 | 2008-12-18 | Gilead Sciences, Inc. | Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders |
| WO2009013286A1 (en) * | 2007-07-24 | 2009-01-29 | Novartis Ag | Organic compounds |
| ATE546448T1 (de) * | 2008-08-02 | 2012-03-15 | Janssen Pharmaceutica Nv | Urotensin-ii-rezeptorantagonisten |
| MX337893B (es) | 2009-11-10 | 2016-03-28 | Celgene Corp | Nanosuspension de un farmaco debilmente soluble preparada por un proceso de microfluidizacion. |
| MX2012004741A (es) * | 2009-11-19 | 2012-05-22 | Celgene Corp | Apremilast para el tratamiento de sarcoidosis. |
| AR079451A1 (es) | 2009-12-18 | 2012-01-25 | Nycomed Gmbh | Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina |
| MX347928B (es) * | 2011-01-10 | 2017-05-19 | Celgene Corp | Derivados de fenetilsulfona isoindolina y su uso. |
| BR112016003454B1 (pt) * | 2013-08-23 | 2023-02-14 | Reata Pharmaceuticals, Inc. | Uso de composto de metil bardoxolona |
| JP2016540041A (ja) * | 2013-11-06 | 2016-12-22 | セルジーン コーポレイション | Ｐｄｅ４モジュレーターによるウイルス性疾患の治療のための組成物及び方法 |
| WO2017030892A1 (en) | 2015-08-14 | 2017-02-23 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
| CA3015700A1 (en) * | 2015-09-10 | 2017-03-16 | Key-Pharma Biomedical Inc. | The use of kauranes compounds in the manufacture of medicament for treatment of cardiac hypertropy and pulmonary hypertension |
| KR102486434B1 (ko) | 2016-11-08 | 2023-01-09 | 리아타 파마슈티컬즈 홀딩스, 엘엘씨 | 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법 |
| CN111170925B (zh) * | 2020-01-09 | 2023-01-17 | 常州大学 | 作为pde2/4双重抑制剂的邻苯二甲酰亚胺类化合物及其制备方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| WO1995003009A1 (en) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| WO1995003807A1 (en) * | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5801195A (en) * | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
| US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
| IT1274549B (it) * | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
| US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
| US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
| RU2188819C2 (ru) * | 1996-08-12 | 2002-09-10 | Селджин Корпорейшн | НОВЫЕ ИММУНОТЕРАПЕВТИЧЕСКИЕ СОЕДИНЕНИЯ, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ ФДЭ, TNFα И NFκB |
| FR2762841B1 (fr) * | 1997-04-30 | 1999-07-02 | Jouveinal Inst Rech | Diazepino-indolones inhibitrices de phosphodiesterases iv |
| CA2295295A1 (en) * | 1997-07-31 | 1999-02-11 | Celgene Corporation | Substituted alkanohydroxamic acids and method of reducing tnf.alpha. levels |
| US6015803A (en) * | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) * | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) * | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| FR2792938B1 (fr) * | 1999-04-28 | 2001-07-06 | Warner Lambert Co | NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV |
| US7235237B2 (en) * | 1999-10-29 | 2007-06-26 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
| HUP0000920A3 (en) * | 2000-02-28 | 2002-03-28 | Sanofi Synthelabo | Pde4 inhibitor isoquinolinylidene derivatives, process for their preparation and medicaments containing them |
| US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US20040077624A1 (en) * | 2002-05-23 | 2004-04-22 | Pfizer Inc. | Novel combination |
| WO2004054501A2 (en) * | 2002-11-18 | 2004-07-01 | Celgene Corporation | Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| WO2004078144A2 (en) * | 2003-03-05 | 2004-09-16 | Celgene Corporation | Diphenylethylene compounds and uses thereof |
| US7034052B2 (en) * | 2003-03-12 | 2006-04-25 | Celgene Corporation | 7-Amido-isoindolyl compounds and their pharmaceutical uses |
| US6911464B2 (en) * | 2003-03-12 | 2005-06-28 | Celgene Corporation | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses |
| CA2590903A1 (en) * | 2004-12-13 | 2006-06-22 | Celgene Corporation | Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation |
-
2005
- 2005-04-21 US US11/111,187 patent/US20050239867A1/en not_active Abandoned
- 2005-04-21 WO PCT/US2005/013597 patent/WO2005102317A1/en not_active Ceased
- 2005-04-21 BR BRPI0510166-2A patent/BRPI0510166A/pt not_active IP Right Cessation
- 2005-04-21 CA CA002563377A patent/CA2563377A1/en not_active Abandoned
- 2005-04-21 EP EP05749368A patent/EP1755589A4/en not_active Withdrawn
- 2005-04-21 MX MXPA06012279A patent/MXPA06012279A/es not_active Application Discontinuation
- 2005-04-21 JP JP2007509624A patent/JP2007533760A/ja not_active Abandoned
- 2005-04-21 AU AU2005234783A patent/AU2005234783A1/en not_active Abandoned
- 2005-04-21 KR KR1020067024520A patent/KR20070007945A/ko not_active Withdrawn
- 2005-04-21 ZA ZA200609228A patent/ZA200609228B/en unknown
- 2005-04-21 CN CNA2005800211887A patent/CN1972684A/zh active Pending
-
2006
- 2006-10-22 IL IL178788A patent/IL178788A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007533760A5 (https=) | ||
| JP5806320B2 (ja) | 肺高血圧症を処置するための組成物および方法 | |
| CN100430048C (zh) | 治疗下泌尿道症状的α-2-δ配体 | |
| JP2007506740A5 (https=) | ||
| RU2013138569A (ru) | Антагонисты рецептора минералокортикоидов | |
| JP2008523102A5 (https=) | ||
| JP2014502979A5 (https=) | ||
| JP2013531070A5 (https=) | ||
| ZA200609228B (en) | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension | |
| IL287159B1 (en) | Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use | |
| CA2533747A1 (en) | Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors | |
| JP2007502265A5 (https=) | ||
| US20060183787A1 (en) | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | |
| JP2012517441A5 (https=) | ||
| JP2004529145A5 (https=) | ||
| JP2006511606A (ja) | 下部尿路症状を治療するα−２−δリガンド | |
| EP1363628A2 (en) | Drugs for sex dysfunctions | |
| JP2006507359A5 (https=) | ||
| MX2015006270A (es) | Formas polimorfas. | |
| RU2222529C2 (ru) | Производные бензамидина | |
| CN1612855A (zh) | 逆转和预防心血管疾病的方法 | |
| CN1914151A (zh) | 作为环氧合酶－2抑制剂的二芳基－2(5h)－呋喃酮类的释放一氧化氮的前药 | |
| RU2002108346A (ru) | Фармацевтическая композиция | |
| JP5738205B2 (ja) | アトルバスタチンラクトールの薬物としての使用 | |
| WO1999043318A1 (en) | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBTORS |